Trial Profile
Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Randomised Controlled Trial
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Gastroenteritis
- Focus Therapeutic Use
- 25 Apr 2019 Primary endpoint (Duration of diarrhea)has not been met as per results published in the Pediatric Infectious Disease Journal
- 25 Apr 2019 Results published in the Pediatric Infectious Disease Journal
- 28 Jan 2019 Status changed from recruiting to completed.